Futura Medical plc (FAMDF)
USD 0.38
(0.0%)
USD 0.38
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.81 Million GBP | 82.56% |
| 2022 | 6.47 Million GBP | -45.16% |
| 2021 | 11.8 Million GBP | 628.54% |
| 2020 | 1.62 Million GBP | -66.95% |
| 2019 | 4.9 Million GBP | -54.94% |
| 2018 | 10.87 Million GBP | 13.25% |
| 2017 | 9.6 Million GBP | -28.53% |
| 2016 | 13.43 Million GBP | 143.67% |
| 2015 | 5.51 Million GBP | -46.61% |
| 2014 | 10.32 Million GBP | 604.73% |
| 2013 | 1.46 Million GBP | -54.31% |
| 2012 | 3.2 Million GBP | 8.68% |
| 2011 | 2.95 Million GBP | 180.34% |
| 2010 | 1.05 Million GBP | -49.3% |
| 2009 | 2.07 Million GBP | 100.1% |
| 2008 | 1.03 Million GBP | -66.39% |
| 2007 | 3.08 Million GBP | -26.2% |
| 2006 | 4.18 Million GBP | 88.72% |
| 2005 | 2.21 Million GBP | -44.2% |
| 2004 | 3.97 Million GBP | 53.46% |
| 2003 | 2.58 Million GBP | 46.6% |
| 2002 | 1.76 Million GBP | -21.89% |
| 2001 | 2.26 Million GBP | 572.92% |
| 2000 | 336 Thousand GBP | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 9.46 Million GBP | -19.89% |
| 2024 Q2 | 9.46 Million GBP | 0.0% |
| 2023 Q3 | 11.81 Million GBP | 15.76% |
| 2023 Q1 | 10.2 Million GBP | 57.7% |
| 2023 FY | 11.81 Million GBP | 82.56% |
| 2023 Q2 | 10.2 Million GBP | 0.0% |
| 2023 Q4 | 11.81 Million GBP | 0.0% |
| 2022 Q3 | 6.47 Million GBP | -26.16% |
| 2022 Q4 | 6.47 Million GBP | 0.0% |
| 2022 FY | 6.47 Million GBP | -45.16% |
| 2022 Q1 | 8.76 Million GBP | -25.73% |
| 2022 Q2 | 8.76 Million GBP | 0.0% |
| 2021 Q3 | 11.8 Million GBP | -13.93% |
| 2021 Q2 | 13.71 Million GBP | 0.0% |
| 2021 Q1 | 13.71 Million GBP | 746.42% |
| 2021 FY | 11.8 Million GBP | 628.54% |
| 2021 Q4 | 11.8 Million GBP | 0.0% |
| 2020 Q2 | 3.06 Million GBP | 0.0% |
| 2020 FY | 1.62 Million GBP | -66.95% |
| 2020 Q1 | 3.06 Million GBP | -37.39% |
| 2020 Q3 | 1.62 Million GBP | -47.21% |
| 2020 Q4 | 1.62 Million GBP | 0.0% |
| 2019 Q2 | 7.98 Million GBP | 0.0% |
| 2019 Q1 | 7.98 Million GBP | -26.57% |
| 2019 FY | 4.9 Million GBP | -54.94% |
| 2019 Q3 | 4.9 Million GBP | -38.64% |
| 2019 Q4 | 4.9 Million GBP | 0.0% |
| 2018 Q2 | 7.78 Million GBP | 0.0% |
| 2018 Q3 | 10.87 Million GBP | 39.65% |
| 2018 FY | 10.87 Million GBP | 13.25% |
| 2018 Q1 | 7.78 Million GBP | -18.9% |
| 2018 Q4 | 10.87 Million GBP | 0.0% |
| 2017 Q2 | 11.64 Million GBP | 0.0% |
| 2017 Q1 | 11.64 Million GBP | -13.31% |
| 2017 FY | 9.6 Million GBP | -28.53% |
| 2017 Q4 | 9.6 Million GBP | 0.0% |
| 2017 Q3 | 9.6 Million GBP | -17.55% |
| 2016 Q2 | 3.66 Million GBP | 0.0% |
| 2016 FY | 13.43 Million GBP | 143.67% |
| 2016 Q4 | 13.43 Million GBP | 0.0% |
| 2016 Q3 | 13.43 Million GBP | 266.85% |
| 2016 Q1 | 3.66 Million GBP | -33.58% |
| 2015 Q1 | 8.24 Million GBP | -20.22% |
| 2015 Q4 | 5.51 Million GBP | 0.0% |
| 2015 Q3 | 5.51 Million GBP | -33.07% |
| 2015 Q2 | 8.24 Million GBP | 0.0% |
| 2015 FY | 5.51 Million GBP | -46.61% |
| 2014 Q1 | 11.59 Million GBP | 690.81% |
| 2014 Q2 | 11.59 Million GBP | 0.0% |
| 2014 Q3 | 10.32 Million GBP | -10.89% |
| 2014 FY | 10.32 Million GBP | 604.73% |
| 2014 Q4 | 10.32 Million GBP | 0.0% |
| 2013 Q1 | 2.4 Million GBP | -25.07% |
| 2013 FY | 1.46 Million GBP | -54.31% |
| 2013 Q3 | 1.46 Million GBP | -39.03% |
| 2013 Q2 | 2.4 Million GBP | 0.0% |
| 2013 Q4 | 1.46 Million GBP | 0.0% |
| 2012 Q4 | 3.2 Million GBP | 0.0% |
| 2012 Q2 | 2.19 Million GBP | 0.0% |
| 2012 FY | 3.2 Million GBP | 8.68% |
| 2011 Q2 | 3.7 Million GBP | 0.0% |
| 2011 Q4 | 2.95 Million GBP | 0.0% |
| 2011 FY | 2.95 Million GBP | 180.34% |
| 2010 FY | 1.05 Million GBP | -49.3% |
| 2010 Q2 | 1.58 Million GBP | 0.0% |
| 2010 Q4 | 1.05 Million GBP | 0.0% |
| 2009 FY | 2.07 Million GBP | 100.1% |
| 2009 Q4 | 2.07 Million GBP | 0.0% |
| 2009 Q2 | 1.29 Million GBP | 0.0% |
| 2008 Q2 | 2.04 Million GBP | 0.0% |
| 2008 Q4 | 1.03 Million GBP | 0.0% |
| 2008 FY | 1.03 Million GBP | -66.39% |
| 2007 Q4 | 3.08 Million GBP | 0.0% |
| 2007 Q2 | 3.4 Million GBP | 0.0% |
| 2007 FY | 3.08 Million GBP | -26.2% |
| 2006 Q4 | 4.18 Million GBP | 0.0% |
| 2006 FY | 4.18 Million GBP | 88.72% |
| 2006 Q2 | 1.67 Million GBP | 0.0% |
| 2005 Q2 | 3.09 Million GBP | 0.0% |
| 2005 Q4 | 2.21 Million GBP | 0.0% |
| 2005 FY | 2.21 Million GBP | -44.2% |
| 2004 Q2 | 4.6 Million GBP | 0.0% |
| 2004 FY | 3.97 Million GBP | 53.46% |
| 2004 Q4 | 3.97 Million GBP | 0.0% |
| 2003 FY | 2.58 Million GBP | 46.6% |
| 2002 FY | 1.76 Million GBP | -21.89% |
| 2001 FY | 2.26 Million GBP | 572.92% |
| 2000 FY | 336 Thousand GBP | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 69.582% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -63.667% |
| SQZ Biotechnologies Company | 107.18 Million USD | 88.976% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -11.961% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 90.925% |
| Mesoblast Limited | 667.9 Million USD | 98.231% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -16228.823% |
| Genus plc | 1.02 Billion USD | 98.852% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -769.903% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2267.822% |
| Marizyme, Inc. | 22.01 Million USD | 46.326% |
| ContraFect Corporation | 20.67 Million USD | 42.858% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1784.586% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2926.993% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2991.854% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -725.146% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -185.005% |
| MultiCell Technologies, Inc. | 126.22 USD | -9361612.09% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1157.475% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 90.805% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2637.079% |
| Q BioMed Inc. | 3.51 Million USD | -236.12% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 66.411% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1433.309% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -4422.539% |
| Biomind Labs Inc. | 73.81 Thousand USD | -15907.197% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 462.85 Million USD | 97.447% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 60.632% |
| Skye Bioscience, Inc. | 11.94 Million USD | 1.039% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -256.665% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -330.259% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -503.433% |
| IMV Inc. | 31.33 Million USD | 62.289% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1618.777% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -353.917% |
| GB Sciences, Inc. | 103.44 Thousand USD | -11323.168% |
| Alpha Cognition Inc. | 2.45 Million USD | -381.873% |
| HST Global, Inc. | 1526.00 USD | -774235.059% |
| CSL Limited | 38.02 Billion USD | 99.969% |
| Halberd Corporation | 10.13 Thousand USD | -116535.604% |
| Enzolytics Inc. | 361.7 Million USD | 96.733% |
| Resverlogix Corp. | 8.11 Million USD | -45.611% |
| Affymax, Inc. | 7.44 Million USD | -58.758% |
| SYBLEU INC | 330.46 Thousand USD | -3475.642% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -529.239% |
| argenx SE | 4.54 Billion USD | 99.74% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 57.714% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 75.229% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -51769.334% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -32.039% |
| AVAX Technologies, Inc. | 7.37 Million USD | -60.175% |
| Zenith Capital Corp. | 7410.00 USD | -159364.953% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.651% |
| Ember Therapeutics, Inc. | 184.00 USD | -6421830.978% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -3571.887% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -4421.033% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 97.352% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -715.572% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 3.02 Million USD | -290.612% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 77.579% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1173.367% |
| BioStem Technologies, Inc. | 14.56 Million USD | 18.845% |
| ONE Bio Corp. | 70.08 Million USD | 83.14% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -20596.313% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -511430.433% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1096.027% |
| Agentix Corp. | 261.39 Thousand USD | -4420.549% |
| LadRx Corporation | 2.3 Million USD | -412.0% |
| Cell Source, Inc. | 195.17 Thousand USD | -5954.359% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2358.887% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3241.568% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3241.568% |
| NovAccess Global Inc. | 62.24 Thousand USD | -18882.703% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1747.298% |
| Itoco Inc. | 1.4 Million USD | -743.982% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -12252.837% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -11047.503% |
| Kadimastem Ltd | 2.3 Million USD | -412.845% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -15375.748% |
| CytoDyn Inc. | 11.13 Million USD | -6.109% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -8164.802% |
| Mobile Lads Corp. | 52.00 USD | -22723655.769% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -65986.985% |
| Qrons Inc. | 420.00 USD | -2813317.381% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2965.432% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2040.178% |
| Rebus Holdings, Inc. | 5000.00 USD | -236227.06% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2786.106% |
| International Stem Cell Corporation | 5.39 Million USD | -119.227% |
| Bioxytran, Inc. | 137.63 Thousand USD | -8485.095% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 21.234% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 28.727% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -14857.409% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1266.563% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -57.195% |
| Neutra Corp. | 2851.00 USD | -414363.451% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 63.537% |
| PureTech Health plc | 693.97 Million USD | 98.297% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -46.403% |
| IXICO plc | 15.84 Million USD | 25.42% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -42.675% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 88.564% |
| CSL Limited | 38.02 Billion USD | 99.969% |
| Cellectis S.A. | 333.99 Million USD | 96.462% |